高危黑色素瘤患者接受4周高剂量干扰素α-2b诱导治疗的III期随机研究:东部肿瘤协作组-美国放射影像网络癌症研究组试验(E1697)
本研究为国际多中心III期随机试验,纳入1150例手术切除的中危黑色素瘤患者,随机接受4周静脉高剂量干扰素α-2b诱导治疗或观察。中位随访7年,两组5年无复发生存率和总生存率均无显著差异,治疗组3级及以上毒性显著更高且生活质量更差。结论认为4周静脉诱导作为东部肿瘤协作组高剂量干扰素方案的一部分,并不优于单纯观察。
要点
- 中危黑色素瘤术后4周静脉高剂量干扰素α-2b诱导治疗与观察相比,5年无复发生存率均为0.70(P=0.964)。
- 两组5年总生存率均为0.83(P=0.558),无显著差异。
- 治疗组3级及以上毒性发生率为57.9%,观察组为4.6%(P<0.001),治疗组生活质量更差。
核心结论
- 对于本试验定义的中危黑色素瘤患者,4周静脉诱导作为东部肿瘤协作组高剂量干扰素方案的一部分,并不优于单纯观察。
研究设计与样本
- 国际多中心III期随机试验,纳入1150例手术切除的皮肤黑色素瘤患者,分层因素包括病理淋巴结状态、淋巴结分期程序、Breslow厚度、原发灶溃疡和疾病分期。
- 患者随机接受干扰素α-2b 20 MU/m2/d静脉注射,每周5天(周一至周五),共4周,或接受观察。
- 主要终点为无复发生存期,次要终点包括总生存期、毒性和生活质量。
主要发现
- 中位随访7年时,观察组5年无复发生存率为0.70(95%CI 0.66-0.74),干扰素组为0.70(95%CI 0.66-0.74),P=0.964。
- 观察组5年总生存率为0.83(95%CI 0.79-0.86),干扰素组为0.83(95%CI 0.80-0.86),P=0.558。
- 治疗相关3级及以上毒性发生率观察组为4.6%,干扰素组为57.9%,P<0.001。
- 治疗组生活质量较观察组更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in patients with surgically resected intermediate-risk melanoma. Patients and Methods In this intergroup international trial, eligible patients had surgically resected cutaneous melanoma in the following categories: (1) T2bN0, (2) T3a-bN0, (3) T4a-bN0, and (4) T1-4N1a-2a (microscopic). Patients were randomly assigned to receive IFN α-2b at 20 MU/m2/d IV for 5 days (Monday to Friday) every week for 4 weeks (IFN) or OBS. Stratification factors were pathologic lymph node status, lymph node staging procedure, Breslow depth, ulceration of the primary lesion, and disease stage. The primary end point was relapse-free survival. Secondary end points included overall survival, toxicity, and quality of life. Results A total of 1,150 patients were randomly assigned. At a median follow-up of 7 years, the 5-year relapse-free survival rate was 0.70 (95% CI, 0.66 to 0.74) for OBS and 0.70, (95% CI, 0.66 to 0.74) for IFN ( P = .964). The 5-year overall survival rate was 0.83 (95% CI, 0.79 to 0.86) for OBS and 0.83 (95% CI, 0.80 to 0.86) for IFN ( P = .558). Treatment-related grade 3 and higher toxicity was 4.6% versus 57.9% for OBS and IFN, respectively ( P < .001). Quality of life was worse for the treated group. Conclusion Four weeks of IV induction as part of the Eastern Cooperative Oncology Group high-dose IFN regimen is not better than OBS alone for patients with intermediate-risk melanoma as defined in this trial.
引用
- Agarwala SS, Lee SJ, Yip W, et al. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017. PMID: 28135150. doi:10.1200/JCO.2016.70.2951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。